Welcome to Paid Research Studies


Browse Locations ... United States» ... West Virginia» ... Charleston






  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Daunorubicin Hydrochloride;   Drug: Pegaspargase;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Doxorubicin Hydrochloride;   Drug: Thioguanine;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Drug: Leucovorin Calcium;   Drug: Etoposide;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Squamous Non-Small Cell Lung Cancer
    Interventions:   Drug: veliparib;   Drug: carboplatin;   Drug: paclitaxel;   Drug: placebo
    Sponsor:   AbbVie
    Recruiting - verified January 2015

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Dexamethasone;   Drug: Vincristine Sulfate;   Drug: Pegaspargase;   Drug: Mitoxantrone Hydrochloride;   Drug: Methotrexate;   Drug: Therapeutic Hydrocortisone;   Drug: Cytarabine;   Drug: Leucovorin Calcium;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Asparaginase;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Mercaptopurine;   Drug: Thioguanine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Implantable Cardioverter Defibrillators;   CRT-D Cardiac Resynchronization Therapy Defibrillator
    Intervention:  
    Sponsor:   Boston Scientific Corporation
    Recruiting - verified August 2014

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Biological: Pertuzumab;   Drug: Goserelin Acetate;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis;   Drug: Aromatase Inhibition Therapy;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Critical Limb Ischemia
    Interventions:   Device: Lutonix DCB;   Device: Uncoated PTA Catheter
    Sponsors:   C. R. Bard;   Bard Ltd
    Recruiting - verified January 2015

  • Condition:   Pneumonia, Bacterial
    Interventions:   Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
    Sponsors:   Bayer;   Nektar Therapeutics
    Recruiting - verified January 2015

  • Conditions:   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Atrial Fibrillation
    Intervention:   Other: Patients with Atrial Fibrillation
    Sponsors:   Janssen Scientific Affairs, LLC;   Duke Clinical Research Institute
    Recruiting - verified January 2015

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Stroke;   Atrial Fibrillation
    Intervention:  
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified January 2015

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Childhood Acute Erythroid Leukemia;   Childhood Acute Megakaryoblastic Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Daunorubicin Hydrochloride;   Drug: Mitoxantrone Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Bortezomib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Fungal Infection;   Neutropenia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: caspofungin acetate;   Drug: fluconazole;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
    Interventions:   Radiation: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Drug: Lenalidomide;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Hypertension
    Interventions:   Drug: Aliskiren;   Drug: Enalapril
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified January 2015

  • Conditions:   Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
    Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Erlotinib Hydrochloride;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Hepatoblastoma;   Stage I Childhood Hepatocellular Carcinoma;   Stage II Childhood Hepatocellular Carcinoma;   Stage III Childhood Hepatocellular Carcinoma;   Stage IV Childhood Hepatocellular Carcinoma
    Interventions:   Procedure: Therapeutic Conventional Surgery;   Drug: Cisplatin;   Drug: Fluorouracil;   Drug: Vincristine Sulfate;   Drug: Doxorubicin Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Temsirolimus;   Procedure: Liver Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
    Interventions:   Drug: Lenalidomide;   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Brain Injuries
    Intervention:   Drug: NNZ-2566
    Sponsor:   Neuren Pharmaceuticals Limited
    Recruiting - verified January 2015

  • Conditions:   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
    Interventions:   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014